NASDAQ Framework: Protagonist Therapeutics Inc.
Clinical-stage biopharmaceutical company developing peptide-based drugs 1.
1: Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. View Source
Protagonist Therapeutics, Inc., headquartered in Newark, California, is a clinical-stage biopharmaceutical company focused on developing peptide-based drugs for hematology, blood disorders, and inflammatory and immunomodulatory diseases. The company's pipeline includes Rusfertide (PTG-300), an injectable hepcidin mimetic for polycythemia vera, and JNJ-2113, an orally delivered investigational drug for moderate-to-severe plaque psoriasis. Protagonist has established strategic collaborations with Takeda and JNJ Innovative Medicines to co-develop and commercialize these therapies. The company's proprietary technology platform enables the discovery and development of novel peptide-based new chemical entities (NCEs) aimed at transforming treatment paradigms in disease areas with significant unmet medical needs 23.
2: Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. View Source3: Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities (NCEs) that can potentially transform existing treatment paradigms in disease areas with significant unmet medical needs. Our platform enables us to discover peptides in a de novo fashion with the desired degree of potency, specificity and selectivity, and also engineer oral stability with specific peptidomimetic and chemical modifications. View Source
4: Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one ... ACCESSWIRE • 2 days ago Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. PR Newswire • 27 days ago Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Patients receiving rusfertide ... ACCESSWIRE • last month Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 NEWARK, CA / ACCESSWIRE / May 31, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings ... ACCESSWIRE • last month Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral ... ACCESSWIRE • 2 months ago Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and investor ... ACCESSWIRE • 2 months ago Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027 [1] Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis ... ACCESSWIRE • 2 months ago Turnstone Biologics Appoints William Waddill to its Board of Directors SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o GlobeNewswire • 3 months ago Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data On track to achieve 250 patient enrollment target in March 2024 Top-line data for 32-week primary endpoint expected in the first quarter of 2025 NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") ... ACCESSWIRE • 3 months ago Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven ... ACCESSWIRE • 4 months ago Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year Long-term extension (LTE) FRONTIER 2 study demonstrated sustained efficacy and similar safety results from Week 16 to Week 52, consistent with previously reported FRONTIER 1 16-week Phase 2b study The proportion of patients achieving PASI 75, 90 and ... ACCESSWIRE • 4 months ago Protagonist Therapeutics to Participate in Upcoming Investor Conferences NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences: Event: 2024 Jefferies Biotech on the Bay Summit Date: March ... ACCESSWIRE • 4 months ago Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway extended through Q4 2027[1] Two articles published ... ACCESSWIRE • 4 months ago New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera - Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy - Rusfertide was associated with lower disease-related symptoms in patients with ... ACCESSWIRE • 4 months ago Protagonist Therapeutics Reports Granting of Inducement Awards NEWARK, CA / ACCESSWIRE / February 20, 2024 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on February 15, 2024, it issued inducement awards to Sid Reddy, the Company's recently hired Vice President and Controller, in accordance ... ACCESSWIRE • 5 months ago New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, ... ACCESSWIRE • 5 months ago Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development ... ACCESSWIRE • 5 months ago Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 NEWARK, CA / ACCESSWIRE / January 29, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual ... ACCESSWIRE • 5 months ago Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a presentation and host one-on-one ... ACCESSWIRE • 6 months ago Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to ... ACCESSWIRE • 7 months ago View Source5: Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm’s initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn’s disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. View Source
LOW RISK
Protagonist Therapeutics Inc. demonstrates a strong financial position, evidenced by a significant revenue surge driven by a $300 million upfront payment from Takeda, resulting in a net income of $207.34 million for Q1 2024 6. This financial boost has extended the company's operational runway through Q4 2027 7. Additionally, the company has a robust pipeline with promising candidates like Rusfertide and JNJ-2113, which are in advanced stages of clinical trials 89. These factors, combined with strategic collaborations and a clear path for future developments, indicate a low financial risk for the company.
Protagonist Therapeutics Inc. demonstrates a strong financial position, evidenced by a significant revenue surge driven by a $300 million upfront payment from Takeda, resulting in a net income of $207.34 million for Q1 2024 6. This financial boost has extended the company's operational runway through Q4 2027 7. Additionally, the company has a robust pipeline with promising candidates like Rusfertide and JNJ-2113, which are in advanced stages of clinical trials 89. These factors, combined with strategic collaborations and a clear path for future developments, indicate a low financial risk for the company.
6: Protagonist Therapeutics reported an exceptional increase in its license and collaboration revenue, which soared to $254.95 million for the quarter, compared to none in the same period last year. This remarkable increase is attributed to the $300 million upfront payment from Takeda, part of a broader collaboration aimed at co-developing and co-commercializing rusfertide. This influx of capital has significantly strengthened the company's financial position, with net income reaching $207.34 million, or $3.41 per basic share, a drastic improvement from a net loss of $33.73 million, or $0.67 per basic share, in Q1 2023. View Source7: On May 7, 2024, Protagonist Therapeutics Inc (NASDAQ:PTGX) unveiled its financial outcomes for the first quarter ended March 31, 2024, through its 8-K filing. The clinical-stage biopharmaceutical company reported a significant revenue surge, primarily driven by a lucrative collaboration with Takeda. This partnership not only bolstered its financial standing but also extended its operational runway, promising sustained advancements in its peptide-based therapeutic developments. View Source8: Protagonist Therapeutics' strategic maneuvers in Q1 2024, particularly the collaboration with Takeda, have not only provided immediate financial benefits but also reinforced the company's pipeline development. The company has successfully completed enrollment for the Phase 3 trials of JNJ-2113 for treating moderate to severe psoriasis, with results anticipated by year-end. This positions JNJ-2113, a novel oral IL-23 receptor antagonist, as a potential leader in psoriasis treatment. View Source9: Moreover, the company's robust pipeline includes rusfertide, currently in a global Phase 3 development program for polycythemia vera. Positive results from earlier trials suggest promising prospects for this candidate. Protagonist Therapeutics also plans to nominate a development candidate from its oral IL-17 program by the end of 2024, further expanding its clinical portfolio. View Source
10: Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024 NEWARK, CA / ACCESSWIRE / July 22, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one ... ACCESSWIRE • 2 days ago Protagonist Therapeutics Set to Join S&P SmallCap 600 Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions. PR Newswire • 27 days ago Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia vera Patients receiving rusfertide ... ACCESSWIRE • last month Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024 NEWARK, CA / ACCESSWIRE / May 31, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings ... ACCESSWIRE • last month Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral ... ACCESSWIRE • 2 months ago Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and investor ... ACCESSWIRE • 2 months ago Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027 [1] Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis ... ACCESSWIRE • 2 months ago Turnstone Biologics Appoints William Waddill to its Board of Directors SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company’s Board of Directors. The Company also announced that Patrick Machado has stepped down as a member o GlobeNewswire • 3 months ago Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data On track to achieve 250 patient enrollment target in March 2024 Top-line data for 32-week primary endpoint expected in the first quarter of 2025 NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") ... ACCESSWIRE • 3 months ago Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven ... ACCESSWIRE • 4 months ago Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year Long-term extension (LTE) FRONTIER 2 study demonstrated sustained efficacy and similar safety results from Week 16 to Week 52, consistent with previously reported FRONTIER 1 16-week Phase 2b study The proportion of patients achieving PASI 75, 90 and ... ACCESSWIRE • 4 months ago Protagonist Therapeutics to Participate in Upcoming Investor Conferences NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences: Event: 2024 Jefferies Biotech on the Bay Summit Date: March ... ACCESSWIRE • 4 months ago Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway extended through Q4 2027[1] Two articles published ... ACCESSWIRE • 4 months ago New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera - Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy - Rusfertide was associated with lower disease-related symptoms in patients with ... ACCESSWIRE • 4 months ago Protagonist Therapeutics Reports Granting of Inducement Awards NEWARK, CA / ACCESSWIRE / February 20, 2024 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on February 15, 2024, it issued inducement awards to Sid Reddy, the Company's recently hired Vice President and Controller, in accordance ... ACCESSWIRE • 5 months ago New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ACCESSWIRE / February 7, 2024 / Protagonist Therapeutics, ... ACCESSWIRE • 5 months ago Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development ... ACCESSWIRE • 5 months ago Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024 NEWARK, CA / ACCESSWIRE / January 29, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 6th Annual ... ACCESSWIRE • 5 months ago Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a presentation and host one-on-one ... ACCESSWIRE • 6 months ago Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has earned a $10 million milestone payment following the dosing of the third patient in ANTHEM-UC, a Phase 2b trial to ... ACCESSWIRE • 7 months ago View Source11: Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. View Source12: Moreover, the company's robust pipeline includes rusfertide, currently in a global Phase 3 development program for polycythemia vera. Positive results from earlier trials suggest promising prospects for this candidate. Protagonist Therapeutics also plans to nominate a development candidate from its oral IL-17 program by the end of 2024, further expanding its clinical portfolio. View Source
Protagonist Therapeutics Inc. has outlined a comprehensive product roadmap and expansion strategy for 2024 through 2026, focusing on the advancement and commercialization of its peptide-based therapies. Key initiatives include the global Phase 3 development program for Rusfertide (PTG-300) aimed at treating polycythemia vera, with promising results from earlier trials suggesting significant potential 13. The company is also progressing with Phase 3 trials for JNJ-2113, an oral IL-23 receptor antagonist for moderate to severe psoriasis, with results expected by year-end 2024 14. Additionally, Protagonist plans to nominate a development candidate from its oral IL-17 program by the end of 2024, further diversifying its clinical portfolio 15. Strategic collaborations with Takeda and JNJ Innovative Medicines bolster these efforts, providing financial stability and enhancing the company’s capability to accelerate its core pipeline projects 16.
13: Moreover, the company's robust pipeline includes rusfertide, currently in a global Phase 3 development program for polycythemia vera. Positive results from earlier trials suggest promising prospects for this candidate. Protagonist Therapeutics also plans to nominate a development candidate from its oral IL-17 program by the end of 2024, further expanding its clinical portfolio. View Source14: Protagonist Therapeutics' strategic maneuvers in Q1 2024, particularly the collaboration with Takeda, have not only provided immediate financial benefits but also reinforced the company's pipeline development. The company has successfully completed enrollment for the Phase 3 trials of JNJ-2113 for treating moderate to severe psoriasis, with results anticipated by year-end. This positions JNJ-2113, a novel oral IL-23 receptor antagonist, as a potential leader in psoriasis treatment. View Source15: Moreover, the company's robust pipeline includes rusfertide, currently in a global Phase 3 development program for polycythemia vera. Positive results from earlier trials suggest promising prospects for this candidate. Protagonist Therapeutics also plans to nominate a development candidate from its oral IL-17 program by the end of 2024, further expanding its clinical portfolio. View Source16: The strategic initiatives and financial results reported by Protagonist Therapeutics signify a pivotal phase in the company's growth trajectory. The collaboration with Takeda not only bolsters its financial stability but also enhances its capability to accelerate its core pipeline projects. Investors should note the potential long-term benefits from its diversified portfolio, particularly in the immunology therapeutic area, which could drive substantial value pending successful clinical outcomes and subsequent commercialization phases. View Source